Investors might want to bet on Moleculin Biotech, Inc. (MBRX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a chang ...

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2025. SO WHAT: If you purchased Savara securities during the Class Period y ...

We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.'s share was trading at $59.68 as of September 11th. PTGX’s trailing and forward P/E were 81.75 and 26.39 respectively according to Yahoo Finance. 10 Best Healthcare Dividend Stocks To Buy Protagonist Therapeutics (PTGX) presents a compelling investment case following strong clinical progress and underappr ...

公司融资活动 - Enveric Biosciences宣布签订最终协议立即行使部分A类认股权证可购买总计1,212,499股普通股[1] - 公司同时行使B类认股权证具体购买股数未在原文中完整披露[1] 公司业务定位 - 公司为生物技术企业专注于开发新一代神经可塑性小分子药物[1] - 研发方向针对精神疾病和神经系统疾病治疗领域[1]

行业背景与市场数据 - 2024年全球服装纤维市场规模约为2238亿美元 其中合成纤维占比约59% [4] - 聚酯纤维市场2023年估值1185亿美元 预计2030年达1916亿美元 年复合增长率7.3% [4] - 尼龙纤维市场预计从2024年84.4亿美元增长至2032年129.2亿美元 年复合增长率6-7% [5] - 广义尼龙/聚酰胺市场2023年估值310.9亿美元 预计2032年增长至488.6亿美元 [5] 环境问题与需求转变 - 合成纺织品占海洋中微塑料来源的35%以上 [8] - 尼龙和聚酯纤维在每次洗涤、干燥和穿着过程中释放微塑料颗粒 [3] - 传统塑料基服装需数百年才能分解 造成长期填埋负担 [8] - 监管机构和环保品牌正从"化石基"纺织品转向可持续替代品 [2] 技术解决方案 - 蜘蛛丝技术提供可生物降解的无塑料替代方案 性能优于合成纤维 [2][6][9] - 该材料具有完全生物降解性 不会污染海洋或土壤 [9] - 强度重量比超越多种合成纤维 [9] - 非石油基创新 不含石油或有毒化学品 [9] 公司进展与定位 - Kraig Biocraft Laboratories通过转基因蚕生产专利蜘蛛丝 [1][10] - 公司处于蜘蛛丝开发和商业化全球领先地位 [1] - 目前正准备向三家潜在客户交付首批蜘蛛丝纱线样本 [7] - 蜘蛛丝技术适用于国防、高性能服装、技术纺织品和医疗应用领域 [10]

Nylon and Polyester Are Polluting the Planet with MicroplasticsDENVER, Sept. 17, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today spotlights a major environmental threat that Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, is ideally positioned to address. Spider silk technology offers a biodegradable, plastic-free alternat ...

HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ: HLVX) ( ...

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced it will effect a 1-for-30 reverse split of its common stock at the opening of trading on September 19, 2025. ...

Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts, one as an oral presentation and another as a poster presentation ...

核心观点 - 生物技术行业提供投资组合增长机会 结合医疗需求稳定性和创新潜力[2] - 福泰制药(Vertex Pharmaceuticals)作为囊性纤维化(CF)治疗领域领导者 通过创新药物实现持续收入增长并拓展新治疗领域[3][5][9] - 公司CF核心业务保持强劲 新药Alyftrek覆盖更多突变且疗效提升 同时基因编辑药物Casgevy和疼痛管理药物Journavx逐步贡献收入[7][8][10][11] - 研发管线包含5个关键项目 涉及肾脏疾病和1型糖尿病等领域 支持长期增长潜力[12][13] 财务表现 - 过去十年股价上涨约190%[5] - 自2012年推出CFTR调节剂以来收入持续增长[5] - 基因编辑药物Casgevy已有115名患者完成细胞收集过程 29名患者接受治疗[10] - 疼痛管理药物Journavx在上市4个月内处方量超过11万份[11] 核心CF业务 - Trikafta可覆盖90%的CF患者 继续驱动收入增长[7] - 新药Alyftrek于去年获批 额外覆盖31种基因突变且疗效优于Trikafta[7] - 持续开发其他潜在CF药物 预计将长期保持领域领导地位[8] 业务多元化 - 去年推出血液疾病基因编辑治疗药物Casgevy[9] - 今年进入疼痛管理领域并推出Journavx[9] - Journavx作为非阿片类止痛药 疗效优于非处方产品且无成瘾性[11] - 公司预计疼痛管理药物将创造又一个数十亿美元级业务[11] 研发管线 - 4个项目处于关键开发阶段 即将开始第5个项目[12] - 研发项目包括肾脏疾病(IgA肾病和APOL1介导的肾病) 疼痛管理和1型糖尿病[12] - 即使个别候选药物遇到障碍 公司仍能通过现有管线逐步扩大商业化药物数量和治疗领域[13]